Company Profile

Orgenesis Stock Price, News & Catalysts

Ticker:
ORGS
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

0.26 USD (+1224.75%)

Close

Last updated: November 19, 2026

—

Market cap

Why the stock is moving

As of Nov 19, 2026, ORGS closed up 1224.8% at $0.2650. No new same-company headline was identified in the current news window.

Company overview

Decentralized Cell and Gene Therapy Platform

Orgenesis develops technologies and service models intended to move cell and gene therapy production closer to patients. Its POCare strategy combines therapeutic programs, processing systems, and a distributed network of clinical and manufacturing sites.

POCare Centers and Networks

The company works with hospitals, research institutions, and regional partners to establish point-of-care development and production capabilities. These networks are intended to reduce transportation, time, and infrastructure constraints associated with centralized manufacturing.

Mobile Processing Units and Labs

Orgenesis designs mobile or modular clean-room facilities that can be deployed near treatment centers. Standardized units may support technology transfer and local production without building a large permanent facility for every program.

Cell-Processing Technologies

The platform includes automation, closed-system processing, quality controls, and digital tools for manufacturing advanced therapies. Orgenesis can provide development, engineering, and technology-transfer services to partners.

Partnership-Based Business Model

The company typically collaborates with therapy developers and healthcare institutions rather than commercializing every product independently. Revenue opportunities include development services, licensing, equipment, processing, and participation in partnered programs.

Future catalysts

    Recent news

    1. 01
    2. 02
    3. 03
    4. 04
    5. 05

    Similar stocks

    Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

    Frequently Asked Questions

    What is the current stock price of Orgenesis (ORGS)?

    Orgenesis (ORGS) most recently closed at 0.26 USD, a +1224.75% move versus the previous session.

    What does Orgenesis do?

    Decentralized Cell and Gene Therapy Platform Orgenesis develops technologies and service models intended to move cell and gene therapy production closer to patients. Its POCare strategy combines therapeutic programs, processing systems, and a distributed network of clinical and manufacturing sites. POCare Centers and Networks The company works with...

    On which exchange is ORGS stock listed?

    Orgenesis (ORGS) is associated with NASDAQ, United States, Biopharma.

    What is Decentralized?

    Decentralized Cell and Gene Therapy Platform Orgenesis develops technologies and service models intended to move cell and gene therapy production closer to patients.

    Which conditions is Orgenesis targeting with Decentralized?

    Decentralized Cell and Gene Therapy Platform Orgenesis develops technologies and service models intended to move cell and gene therapy production closer to patients. Its POCare strategy combines therapeutic programs, processing systems, and a distributed network of clinical and manufacturing sites. POCare Centers and Networks The company works with...

    What is Cell?

    Decentralized Cell and Gene Therapy Platform Orgenesis develops technologies and service models intended to move cell and gene therapy production closer to patients.

    What is Gene?

    Decentralized Cell and Gene Therapy Platform Orgenesis develops technologies and service models intended to move cell and gene therapy production closer to patients.